Who is eligible for clinical trial NCT03833154?

Participants must meet protocol criteria for Carcinoma, Non-Small-Cell Lung. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT03833154 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-17

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (NCT03833154)

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.

Who can join: Review the eligibility criteria below.

Location: Research Site — Tuscaloosa, Alabama

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (209 Sites)

Showing the first 25 of 209 sites.

Research Site — Tuscaloosa, Alabama
Research Site — Chandler, Arizona
Research Site — Phoenix, Arizona
Research Site — Tucson, Arizona
Research Site — Duarte, California
Research Site — Long Beach, California
Research Site — Los Angeles, California
Research Site — San Diego, California
Research Site — Newark, Delaware
Research Site — Washington D.C., District of Columbia
Research Site — Bay Pines, Florida
Research Site — Jacksonville, Florida
Research Site — Miami Beach, Florida
Research Site — Orlando, Florida
Research Site — Atlanta, Georgia
Research Site — Atlanta, Georgia
Research Site — Chicago, Illinois
Research Site — Chicago, Illinois
Research Site — Chicago, Illinois
Research Site — Decatur, Illinois
Research Site — Elmhurst, Illinois
Research Site — Naperville, Illinois
Research Site — Fort Wayne, Indiana
Research Site — Cedar Rapids, Iowa
Research Site — Iowa City, Iowa

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Non-Small-Cell Lung

MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California

Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗